Cannabis and psychedelic therapeutics sit at a scientific inflection point. Clinical evidence is mounting for cannabinoids and compounds like psilocybin and MDMA across pain, treatment-resistant depression, PTSD, and neurological conditions. Yet the field still...
Cannabis research no longer stops at national lines. As medical programs mature across the US, Canada, the UK, and beyond, international clinical trial collaboration has become the fastest route to credible data, regulatory approval, and commercial scale. Yet most...
Patients are asking about medical cannabis faster than most providers can answer. Many physicians never received formal training on cannabinoid science, dosing, drug interactions, or the patchwork of state regulations that shape what they can legally recommend. That...
Cannabinoid-based pharmaceuticals are moving from promise to practice, with a growing pipeline of FDA-reviewed candidates targeting epilepsy, pain, sleep, and beyond. Yet the path from molecule to market remains one of the most demanding in the industry. This session...
